The Uromigos

AZGUONC-PRODUCTIONwarmup

<p>Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study, which analyzed cabazitaxel with abiraterone against abiraterone alone for docetaxel-refractory castration-resistant prostate cancer.</p>


ASCO 2024: CHAARTED-2 in Prostate Cancer

Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study, which analyzed cabazitaxel with abiraterone against abiraterone alone for docetaxel-refractory CRPC.

The Uromigos - ASCO 2024: CHAARTED-2 in Prostate Cancer

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtable

Uromigos Live 2024

AUC3

Localized

mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe

ASCO 2024: CHAARTED-2 in Prostate Cancer

Related Podcasts